Urinary and plasma cell-free DNA integrity as biomarkers for prostate cancer urinary and plasma cell-free DNA Integrity as biomarkers for prostate cancer /
Naira Mohamed Mustafa Abdelhamid
Urinary and plasma cell-free DNA integrity as biomarkers for prostate cancer urinary and plasma cell-free DNA Integrity as biomarkers for prostate cancer / قياس درجه تماسك االاحماض النوويه الحره في البول والبلازما كمؤشر حيوى للكشف عن سرطان البروستاتا Naira Mohamed Mustafa Abdelhamid ; Supervised Dina Farouk Elgayar , Walaa Ahmed Rabie , Mahmoud Abdelhamid - Cairo : Naira Mohamed Mustafa Abdelhamid , 2016 - 130 P. : charts , facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Background: Cell free DNA (cfDNA) is DNA circulating freely in blood stream. It originates from different sources including apoptotic cells which generate small fragments of cfDNA and necrotic cells which generate large fragments of cfDNA. cfDNA integrity is the ratio of longer DNA fragments to shorter ones. The purpose of the present study was to assess the utility of plasma and urine cfDNA integrity as non-invasive screening and diagnostic biomarkers for prostate cancer (PCa) in comparison to the well established tPSA. The current study also aimed at detection of superiority of plasma and urine cfDNA integrity regarding their diagnostic efficacy in PCa. Subjects and methods: This study was conducted on (110) subjects divided into three groups; group (I) compromises (46) PCa patients, group (II) compromises (44) patients with benign prostate hyperplasia (BPH) and group (III) compromises (20) apparently healthy individuals as a control group. Plasma and urine cfDNA integrity were measured using SYBR green based quantitative Polymerase chain reaction (qPCR) for ALU repeats by measuring the ratio of longer fragments ALU 247 bp to shorter fragments ALU 115 bp. Results: The results of this study revealed that plasma and urine cfDNA integrity were statistically significantly higher in PCa group compared to BPH group and control group (p<0.001). However, plasma cfDNA integrity was superior to urine cfDNA integrity in discriminating PCa patients from BPH patients and healthy controls. Conclusion: From these results, it could be concluded that plasma and urine cfDNA integrity might be used as both screening and diagnostic tests for prostate cancer.
Benign prostatic hyperplasia Cell free DNA integrity Prostate cancer
Urinary and plasma cell-free DNA integrity as biomarkers for prostate cancer urinary and plasma cell-free DNA Integrity as biomarkers for prostate cancer / قياس درجه تماسك االاحماض النوويه الحره في البول والبلازما كمؤشر حيوى للكشف عن سرطان البروستاتا Naira Mohamed Mustafa Abdelhamid ; Supervised Dina Farouk Elgayar , Walaa Ahmed Rabie , Mahmoud Abdelhamid - Cairo : Naira Mohamed Mustafa Abdelhamid , 2016 - 130 P. : charts , facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Background: Cell free DNA (cfDNA) is DNA circulating freely in blood stream. It originates from different sources including apoptotic cells which generate small fragments of cfDNA and necrotic cells which generate large fragments of cfDNA. cfDNA integrity is the ratio of longer DNA fragments to shorter ones. The purpose of the present study was to assess the utility of plasma and urine cfDNA integrity as non-invasive screening and diagnostic biomarkers for prostate cancer (PCa) in comparison to the well established tPSA. The current study also aimed at detection of superiority of plasma and urine cfDNA integrity regarding their diagnostic efficacy in PCa. Subjects and methods: This study was conducted on (110) subjects divided into three groups; group (I) compromises (46) PCa patients, group (II) compromises (44) patients with benign prostate hyperplasia (BPH) and group (III) compromises (20) apparently healthy individuals as a control group. Plasma and urine cfDNA integrity were measured using SYBR green based quantitative Polymerase chain reaction (qPCR) for ALU repeats by measuring the ratio of longer fragments ALU 247 bp to shorter fragments ALU 115 bp. Results: The results of this study revealed that plasma and urine cfDNA integrity were statistically significantly higher in PCa group compared to BPH group and control group (p<0.001). However, plasma cfDNA integrity was superior to urine cfDNA integrity in discriminating PCa patients from BPH patients and healthy controls. Conclusion: From these results, it could be concluded that plasma and urine cfDNA integrity might be used as both screening and diagnostic tests for prostate cancer.
Benign prostatic hyperplasia Cell free DNA integrity Prostate cancer